A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections

Chinese Medical Journal

Volumn 111, Issue 11, 1998, Pages 1039-1043

  Hou, Fang ^a   Li, Jiatai ^a   Gao, Lei ^a   Chen, Yang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLAVULANIC ACID; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TICARCILLIN; TIMENTIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CLAVULANIC ACID; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN; PNEUMONIA; RESPIRATORY TRACT INFECTIONS; TICARCILLIN; URINARY TRACT INFECTIONS;

EID: 0031790596     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Fass RJ, Prior RB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agent Chemother 1989;33:1268.
2. Kuck NA, Jacobus NV, Petersen PJ, et al. Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agent Chemother 1989;33:1964.
3. Stobberingh EE, Maclaren DM, Schmitz PIM, et al. Comparative invitro activity of piperacillin-tazobactam against recent clinical isolates: a Dutch national multicentre study. J Antimicrob Chemother 1994;34:777.
4. Shlaes DM, Bacghman R, Boylen CT, et al. Piperacillin/ tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infections. J Antimicrob Chemother 1994;34:565.
5. Tan JA, Wishnow RM, Talan DA, et al. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized multicenter study of piperacillin/tazobactam versus ticarcillin/clavulanate. Antimicrob Agent Chemother 1991;35:1081.
6. Aronoff SC, Jacobs MR, Johenning S, et al. Comparative activities of the β-lactamase Inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Antimicrob Agent Chemother 1984;26:580.
7. Coleman K, Griffin DRJ, Page JWJ, et al. In vitro evaluation of BRL 42715, a novel β-lactamase Inhibitor. Antimicrob Agent Chemother 1989;33:1580.
8. Piddock LJV, Jin YF, Turner HL. Activity of 13 β-lactam agents combined with BRL 42715 against β-lactamase producing Gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam. J Antimicrob Chemother 1993;31:89.
9. Kern W, Kennedy SL, Sachdeva M, et al. Evaluation of piperacillin-tazobactam in experimental meningitis caused by a β-lactamase-producing strain of Kl-positive Escherichia coli. Antimicrob Agent Chemother 1990;34:697.
10. Leleu G, Kitzis MD, Vallois JM, et al. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum β-lactamase. Antimicrob Agent Chemother 1994;38:195.